SLC5A1 Antibodies

Sodium/glucose cotransporter 1 (SLC5A1)

Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is offered by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.

.

Gene Information

Human
Gene Name:	SLC5A1
Uniprot:	P13866
Entrez:	6523

Family

Belongs to:
sodium:solute symporter (SSF) (TC 2.A.21) family

Alternative Names

D22S675; High affinity sodium-glucose cotransporter; Na+/glucose cotransporter 1; NAGT; NAGTsodium/glucose cotransporter 1; SGLT1; SGLT1Na(+)/glucose cotransporter 1; SLC5A1; solute carrier family 5 (sodium/glucose cotransporter), member 1; Solute carrier family 5 member 1

Molecular Weight

Mass (kDA):
73.498 kDA

Genomic Context

Human
Location:	22q12.3
Sequence:	22; NC_000022.11 (32043050..32113029)

Tissue Specificity

Expressed mainly in intestine and kidney.

Subcellular Localizations

Membrane; Multi-pass membrane protein.

Diseases

• Diabetes Mellitus
• Malabsorption Syndrome
• Diabetes Mellitus, Experimental
• Hyperglycemia
• Diabetes Mellitus, Non-insulin-dependent
• Malignant Neoplasms
• Congenital Glucose-galactose Malabsorption
• Neoplasms
• Obesity
• Ischemia
• Diarrhea
• Short Bowel Syndrome
• Glycosuria, Renal

• Hypertensive Disease
• Carcinoma
• Kidney Diseases
• Insulin Resistance
• Fibrosis
• Cystic Fibrosis
• Salivary Gland Diseases

Interacting Proteins

• EGFR

Pathways

• Transport
• Glucose Transport
• Localization
• Excretion
• Secretion
• Intestinal Absorption
• Water Transport
• Cell Proliferation
• Insulin Secretion
• Glucose Homeostasis
• Translation
• Endocytosis
• Lactation

• Ion Transport
• Galactose Transport
• Exocytosis
• Glycosylation
• Fructose Transport
• Regeneration
• Gastric Emptying

PTMs

• Phosphorylation
• Glycosylation
• Reduction
• Cleavage
• Acetylation

• Biotinylation
• Oxidation
• Deglycosylation
• Carboxylation
• Dephosphorylation

Research Areas

• Membrane Trafficking and Chaperones

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SLC5A1

Best Uses of the SLC5A1 Marker

If you're looking for an in-depth article on Sodium/glucose cotransporter 1, then you've come to the right place. Learn more about SLC5A1 and its role in various human diseases. For species-specific samples, you can submit your results. Best of all, these results are applicable to all scientists, worldwide. These are some of the most effective uses for the SLC5A1 indicator.

Sodium/glucose cotransporter 1 (SLC5A1)

SLC5A1, also known as NAGT1 and SGLT1, is a sodium/glucose/glucose cotransporter protein gene. Its coding region is located in the cell membrane and is responsible to transport glucose and galactose. These two simple sugars are found in a wide variety of foods and are produced during the digestion of carbohydrates and other substances in the diet.

This active glucose transporter plays an essential role in the absorption or retention of glucose. Cancer cells grow abnormally in the presence of high glucose uptake. Targeting SGLT1 may therefore be a way to reduce energy supply to tumor cells. Moreover SGLT1 downregulation reduced the activity EGFRAKT and ERK pathway, which phosphorylate many of the targets.

The activity of NADPH-oxidase in microparticles of endothelial endothelial cells is increased by high-glucose. This increases endothelial inflammation. It also impairs endothelial functions, which can lead to the development of atherosclerosis. New insights have been provided by the research into the mechanisms that underlie diabetes-associated atherosclerosis.

In vitro, and in vivo studies indicate that larger tumours are associated SGLT1 levels. Downregulation of SGLT1 inhibits the activity of EGFR, which in turn inhibits downstream signalling pathways. SGLT1 is therefore essential for survival of tumor cells in vivo and in vitro.

Despite the evidence of SGLT-1 inhibition being strong, it is not clear if these inhibitors can affect the development of atherosclerosis and cancer. The potential to treat heart disease by inhibiting apoptosis is perhaps the most promising aspect of these drugs. The SGLT-2 inhibitor, dapaglifloflozin, reduces the apoptotic rate in the left ventricle a diabetic mouse model. Similar results were obtained in diabetic cardiomyopathy rats using empagliflozin.

Another important function of SLC5A1 includes regulation of cardiac Ca2+ levels. It also regulates heart contraction. Its inhibition has been associated with improved cardiac contractility in diabetics. Its inhibition could also improve cardiac hypertrophy and heart failure. The effects of the drugs empagliflozin (dapagliflozin), and SGLT-2-inhibitors on cardiac Ca2+ handling may be beneficial for diabetic patients.

Insulin gene treatment is not able to produce enough insulin. This is one of the biggest hurdles. These studies show that insulin therapy can help in this respect. The researchers used synthetic promoter libraries that contain three elements: hepatocyte nuclear factor 1, CAAT/enhancer-binding protein, and glucose response element. SP23137 was selected to continue research using these elements. It led to normoglycemic mice.

Sodium/glucose cotransporter protein 1

The main mechanism that glucose enters cells is through the Na(+) cotransporter Protein 1. Two sodium/glucose-cotransporter proteins are found in the kidney's proximal tubes and work together to facilitate substrate transport. Although Na(+) cotransporter protein proteins are found in multiple tissues, they don't require N-glycosylation to perform their functions.

Boster Bio's antibodies have high affinity and sensitivity levels, making them ideal for diagnostic and research purposes. They have been validated and optimized for WB, ELISA, and Flow. Boster Bio antibodies have been validated against 250 different tissues and untransfected cells. Boster Bio supplies high-quality ELISA tests and immunological reagents.

Sodium/glucose cotransporter protein 1's role in various human diseases

Sodium/glucose cotransporter protein 1 (SLC5A1) is a member of the sodium-dependent glucose transporter family. This integral membrane protein plays a key role in dietary glucose uptake through the intestinal lumen. SLC5A1 gene mutations have been shown to cause glucose-galactose malabsorption. Multiple transcript variants for the SLC5A1 genome have been identified in people, which has led to the development and evolution of multiple isoforms.

A recent study found that LfhA plays important roles in many human diseases, such as diabetes and Alzheimer’s disease. This protein also regulates the cellular antioxidant response. It is found in blood serum at a level of 500 mg/ml. It is a 605kDa protein. It has a single N terminal domain and seven conserved domains of Nrf2-ECH homology. Sodium/glucose/glucose transporter protein 1 can be expressed during infection and in other metabolic processes.

Glucose transport plays a vital role in the survival of the body. Its dysfunction can lead directly to dangerous conditions, like diabetic ketoacidosis. Diabetes-related Ketoacidosis is life-threatening. The liver uses ketones to convert fat into fuel. Although this process is necessary to provide energy, the ketones that accumulate in the blood can lead to an acidic state.

Inhibitors for SGLT1 reduce renal reabsorption and inhibit urinary glucose transport. SGLT2 also inhibits insulin peripheral resistance. The role of SGLT1 is not fully understood in human diseases. Despite this knowledge, more research is needed to determine whether the inhibitor is truly effective in a clinical trial.

A Glucose cotransporter 1 inhibitor was used to identify a candidate drug. The Glucose Cotransporter Protein 1 is an enzyme that transports glucose into the bloodstream. It is vital for the body to absorb glucose. It may also play a role with diabetes and other human diseases. This project was made possible by the use a glucoside called phlorizin. This glucoside prevents glucose transport in small intestine, kidney, and small intestine. It is difficult to bioavail and lacks specificity, which can be important in clinical trials.

Studies involving rats found that high fructose diets caused an increase in the expression of SGLT2 inside the kidneys. These results suggest that high fructose diets promote inflammation. It also increases the expression of cytokines which are important determinants for inflammation status. Moreover, L. plantarum improved insulin receptor substrate and kinase B in the kidneys.

LfhA exhibits anti-factorH activity. This antigene can block the alternative compliment pathway. It binds with factor H via outer cell proteins, unlike the nonpathogenic L.interrogans. It also binds purified human factor H, normal horses serum, and anti–factor H monoclonal immunoglobulin.